18β-Glycyrrhetinic acid exerts protective effects against cyclophosphamide-induced hepatotoxicity: potential role of PPARγ and Nrf2 upregulation

Table 2 Serum markers of liver function in control, CP, and CP rats pretreated with 18β-GA

Parameter	Control	CP	CP + 25 mg GA	CP + 50 mg GA
ALT (U/L)	23.58 ± 4.51	85.44 ± 9.77***	49.22 ± 5.78^###	33.26 ± 5.02^###$$
AST (U/L)	39.48 ± 8.03	106.51 ± 10.72***	65.18 ± 11.31^###	45.31 ± 8.69^###$
ALP (U/L)	60.11 ± 6.29	149.43 ± 13.42***	81.55 ± 10.58^###	72.19 ± 15.70^###
γGT (U/L)	11.68 ± 4.07	31.42 ± 5.16***	17.44 ± 3.89^##	14.73 ± 4.26^###
LDH (U/L)	241.19 ± 18.81	467.22 ± 29.71***	317.55 ± 18.93^###	246.02 ± 21.82^###$$
Albumin (g/dL)	3.09 ± 0.63	1.97 ± 0.31*	2.80 ± 0.42	3.11 ± 0.53^#

Data are M ± SD (N = 6)
ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase, γGT gamma-glutamyl transferase, LDH lactate dehydrogenase, CP cyclophosphamide, GA glycyrrhetinic acid, SD standard deviation, vs versus
* P < 0.05 and *** P < 0.001 versus control, ^# P < 0.05, ^## P < 0.01, and ^### P < 0.001 versus CP, and ^$$ P < 0.01 versus CP + 25 mg GA group

ISSN: 1865-3499